Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IP Appeals Court Shifts To Plain Meaning, Summary Judgement Reversals

This article was originally published in The Gray Sheet

Executive Summary

The federal appeals court is increasing its preference of construing claims based on "plain meaning" over the "doctrine of equivalents" in intellectual property litigation, potentially benefiting defendants in medical device patent litigation, according to IP attorneys

You may also be interested in...

J&J, Medtronic Play The Slots Before Appeals Court In Stent Patent Debate

Bare-metal stent intellectual property litigation between Johnson & Johnson/Cordis and Medtronic AVE presented before the Washington, D.C. federal appeals court May 6 hinges on the manufacturing method used to create holes in the devices

Boston Scientific Suit Says J&J’s Cypher Infringes Patent, Asks For Injunction

Opposing patent infringement claims by Boston Scientific and Johnson & Johnson introduce a level of uncertainty as to which firm will initially capture the lion's share of the U.S. drug-eluting stent market

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts